Ask AI
Immunotherapy-Based Management of Gastric/GEJ Cancers

CME

Expert Think Tank: New Developments in Immunotherapy-Based Management of Gastric/GEJ Cancers Across the Disease Continuum

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: June 26, 2026

Expiration: December 25, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Jaffer A. Ajani, MD, FASCO, discusses the impact of recent data and regulatory decisions on immunotherapy-based treatment in the perioperative and advanced settings of gastric/gastroesophageal cancers. Dr. Ajani also discusses the incorporation of SC immunotherapy formulations into practice and the potential clinical implications of promising novel immunotherapy-based combinations.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary. 

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with gastric cancer or GEJ do you provide care for in a typical month?

For those who practice in academic or community settings, please indicate your practice setting: